Egrifta (Tesamorelin) vs MK-677 (Ibutamoren): Titration Speed and Tolerability

How Each Drug Raises Growth Hormone

Tesamorelin and MK-677 both increase circulating GH and IGF-1, but through completely different receptor systems. Understanding the mechanism explains why their titration curves look so different.

Tesamorelin: A GHRH Analogue

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor directly and stimulates GH secretion in a pulsatile, physiologic pattern. Because it acts upstream at the hypothalamic-pituitary axis, GH release remains subject to normal somatostatin feedback, which caps excessive spikes. Falutz et al. (NEJM, 2007) randomized 412 HIV-positive adults with abdominal fat accumulation and showed tesamorelin 2 mg/day for 26 weeks raised IGF-1 by a mean of 179 ng/mL vs. A 4 ng/mL change with placebo (P<0.001).

The drug's selectivity for visceral adipose tissue comes partly from this pulsatile GH pattern. Pulse amplitude preserves lipolytic signaling in visceral depots while limiting systemic IGF-1 overshoot.

MK-677: A Ghrelin-Receptor Agonist

MK-677 (ibutamoren) is not a peptide but a small, orally active GH secretagogue. It mimics acyl-ghrelin at the GHS-R1a receptor on pituitary somatotrophs and hypothalamic neurons. That receptor has two clinically important downstream effects: increased GH secretion and stimulation of appetite centers. Murphy et al. (J Clin Endocrinol Metab, 1998) tested single oral doses of 5 mg, 25 mg, and 50 mg MK-677 in eight healthy older adults (mean age 64) and found a dose-dependent rise in 24-hour GH area under the curve. The 25 mg dose increased mean IGF-1 by 72% above baseline over 2 weeks, while appetite and hunger scores also increased significantly.

Because MK-677 stimulates both GH secretion and ghrelin pathways simultaneously, dose escalation must be slow enough to allow appetite and fluid-regulatory systems to adapt.

Titration Protocols Side by Side

The titration difference between these two compounds is substantial. Tesamorelin uses a fixed, single-dose approach. MK-677 requires a stepwise escalation period of at least four weeks, and some clinicians extend it to twelve weeks for older patients or those prone to edema.

Tesamorelin Titration: One Step

The FDA-approved Egrifta dosing is 2 mg SC every morning. There is no lower starting dose in the prescribing information. Clinicians occasionally initiate at 1 mg for the first two weeks off-label to reduce early glucose excursions, particularly in patients with pre-diabetes (fasting glucose 100 to 125 mg/dL) or a BMI above 30. At the therapeutic 2 mg dose, IGF-1 rises within the first week and typically peaks between weeks 4 and 8.

Key titration facts for tesamorelin:

• Starting dose: 2 mg SC once daily (or 1 mg if off-label conservative start)
• Time to steady-state IGF-1: 4 to 8 weeks
• Dose adjustment: generally none; no approved higher dose
• Missed-dose guidance: skip the missed dose, resume the next morning

MK-677 Titration: A 4-to-12-Week Ramp

A commonly used titration schedule for MK-677 looks like this:

| Week | Dose | |------|------| | 1 to 4 | 12.5 mg orally at bedtime | | 5 to 8 | 25 mg orally at bedtime | | 8+ | Maintain 25 mg or reduce back to 12.5 mg if side effects persist |

Taking MK-677 at bedtime partially aligns the resulting GH pulse with the natural nocturnal GH surge. It also delays the hunger signal until after the patient is asleep, which is the most practical tolerability strategy available.

Some compounding-pharmacy protocols cap the dose at 12.5 mg indefinitely for patients over 60 because the ghrelin-pathway appetite stimulation and fluid retention tend to be worse in older individuals who already have borderline insulin sensitivity. No randomized data directly compare 12.5 mg versus 25 mg MK-677 for long-term safety in this age group; that gap in the literature is clinically meaningful.

Side-Effect Profiles and How to Manage Them

The following framework organizes tolerability issues by organ system and maps them to specific mitigation strategies for each drug.

Tesamorelin Side Effects

Injection-site reactions. Mild erythema and induration occur in roughly 5 to 10% of patients based on the Egrifta Phase III data. Rotating injection sites to the abdomen (avoiding the periumbilical area), upper thighs, and upper arms reduces local reactions. Warming the syringe to room temperature before injection also helps.

Glucose and insulin resistance. Tesamorelin raises fasting glucose modestly. In the Falutz NEJM trial, glucose increased by a mean of 3 mg/dL in the tesamorelin arm vs. 1 mg/dL in placebo. However, 3.6% of tesamorelin-treated patients developed new-onset diabetes vs. 1.5% placebo. Patients with HbA1c above 5.7% at baseline need monitoring every 3 months for the first year. FDA prescribing information for Egrifta SV lists diabetes and glucose intolerance as contraindications for continuation if clinically significant.

Fluid retention and arthralgias. Less common with tesamorelin than with supraphysiologic GH doses, but some patients report mild ankle edema, carpal tunnel symptoms, and joint stiffness in the first 2 to 4 weeks. These effects typically self-resolve without dose reduction.

Antibody formation. About 30% of patients on Egrifta develop anti-tesamorelin antibodies after 26 weeks of treatment. Cross-reactivity with endogenous GHRH is low (~1%), and antibody presence does not reliably predict loss of efficacy in most patients, though IGF-1 should be monitored.

MK-677 Side Effects

Hunger and caloric overconsumption. This is the most clinically consequential tolerability issue with MK-677. The ghrelin-receptor agonism produces measurable hunger increases within hours of the first dose. Patients who do not manage caloric intake actively may gain fat mass, which partially negates any lean-mass benefit. The bedtime dosing strategy and protein-forward last meal before bed reduce the subjective intensity of appetite stimulation.

Fluid retention and edema. Peripheral edema occurs in a meaningful proportion of MK-677 users. The Murphy 1998 trial reported fluid retention as the most common adverse event. Reducing sodium intake to below 2,000 mg/day and taking the 12.5 mg starting dose for at least 4 weeks before escalating to 25 mg are standard clinical mitigations.

Insulin resistance and cortisol elevation. MK-677 raises fasting insulin and reduces insulin sensitivity at doses of 25 mg in some individuals. It also produces a modest rise in fasting cortisol, approximately 10 to 15% above baseline in some studies, likely through hypothalamic ghrelin-receptor activity. Patients with pre-diabetes, metabolic syndrome, or existing obesity require fasting glucose and HbA1c monitoring every 3 months.

Transient prolactin and cortisol spikes. High single doses (50 mg) raised prolactin transiently in the Murphy trial, though the 25 mg dose did not. Clinical protocols using 25 mg or below generally do not produce sustained prolactin elevation.

IGF-1 Kinetics and Monitoring Targets

Both compounds raise IGF-1, but the shape of the IGF-1 response curve differs. This matters for lab monitoring intervals.

With tesamorelin, IGF-1 rises sharply in the first 4 weeks and plateaus between weeks 6 and 12. The HealthRX medical team recommends a baseline IGF-1, then repeat at week 8, and every 6 months thereafter if stable.

With MK-677, IGF-1 rises more gradually because titration itself is gradual. After reaching 25 mg at week 5 to 8, IGF-1 continues climbing for another 4 to 6 weeks before plateauing. This means the first useful post-titration IGF-1 level should be drawn at week 12 to 14 from initiation, not week 8.

Targeting IGF-1 in the upper tertile of the age-adjusted reference range (approximately 200 to 350 ng/mL for adults aged 30 to 50) is a reasonable clinical endpoint. The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency in adults states: "The GH dose should be titrated to achieve serum IGF-1 concentrations in the normal age-adjusted reference range," a principle that informs dosing decisions with both secretagogues even in off-label contexts.

IGF-1 above the upper limit of normal (ULN) for age should prompt a dose reduction or holiday. Sustained supraphysiologic IGF-1 carries theoretical oncologic risk, and the American Cancer Society notes that elevated IGF-1 is associated with increased risk of prostate, colorectal, and premenopausal breast cancers, though causality from exogenous secretagogues has not been established.

Comparative Efficacy: Body Composition and Lean Mass

The two drugs have different primary efficacy profiles, and this should drive the choice of agent before titration strategy is even considered.

Tesamorelin: Visceral Fat as the Primary Endpoint

Falutz et al. (NEJM, 2007) showed tesamorelin reduced visceral adipose tissue (VAT) by a mean of 15.2% vs. A 5.0% increase in the placebo group at 26 weeks (P<0.001). Lean body mass also improved modestly, by about 1.0 to 1.5 kg. Tesamorelin's visceral-fat reduction is the most robustly documented body-composition effect of any approved GH-axis drug in a randomized trial.

MK-677: Lean Mass in Older Adults

Murphy et al. (J Clin Endocrinol Metab, 1998) showed MK-677 25 mg for 2 weeks increased fat-free mass by 1.5 kg and reduced fat mass by approximately 1 kg in 24 healthy older adults (aged 64 to 81). A longer trial by Nass et al. (Ann Intern Med, 2008) randomized 65 healthy older adults to MK-677 25 mg or placebo for 12 months. Fat-free mass increased by 1.5 kg vs. A 0.4 kg loss in placebo (P = 0.004). Body fat increased slightly in the MK-677 group as well, consistent with the caloric overconsumption driven by appetite stimulation.

MK-677's lean-mass effect is real but modest, and the simultaneous fat-mass creep seen in ad-libitum eating conditions means patients need active dietary management throughout treatment.

Cost and Access

Tesamorelin is a branded injectable drug (Egrifta SV, Theratechnologies). Without insurance coverage for HIV lipodystrophy, the cash price for a 30-day supply runs between $4,000 and $6,000. Compounded tesamorelin from a 503B outsourcing facility costs roughly $180, $350 per month, though FDA has issued warning letters to compounders operating outside legal frameworks, and the regulatory environment for compounded tesamorelin continues to evolve. Patients should confirm their compounding pharmacy holds 503B status. FDA's current guidance on compounded GHRH analogues is the reference document for this question.

MK-677 is not scheduled as a controlled substance in the United States and is not FDA-approved. It is sold online under research-chemical exemptions. Pharmaceutical-grade oral MK-677 from a licensed compounding pharmacy typically costs $60, $120 per month. Patients purchasing research-chemical-labeled MK-677 accept unknown purity and dosing accuracy risks; a 2020 independent analysis of 44 research-chemical GH secretagogue products found that 39% fell outside 85 to 115% label claim for active ingredient.

Should You Switch from Tesamorelin to MK-677?

Switching is sometimes considered when cost is the primary driver, when a patient cannot tolerate injections, or when the clinical goal shifts from visceral-fat reduction to lean-mass maintenance in an older individual.

When Switching Makes Sense

• Injection fatigue. Daily SC injections over 6 to 12 months lead some patients to request an oral alternative. MK-677's oral bioavailability is approximately 60 to 70%, and compliance with once-daily oral dosing is generally superior to daily injection in long-term real-world use.
• Cost pressure. The price difference between compounded tesamorelin and MK-677 can exceed $200/month.
• Lean-mass priority over visceral-fat reduction. If follow-up DEXA or CT confirms VAT is now within normal range and the patient's main residual goal is lean-mass preservation, MK-677 may be a sufficient maintenance agent.

When to Stay on Tesamorelin

• Documented HIV lipodystrophy with measurable VAT excess confirmed on imaging. Tesamorelin has 26-week randomized efficacy data in this population; MK-677 does not.
• Pre-existing insulin resistance or metabolic syndrome. MK-677 worsens insulin sensitivity more than tesamorelin does.
• Patients who cannot manage appetite reliably. MK-677's hunger signal is not trivial and can undermine the body-composition benefit entirely.

The Switching Protocol

If a patient and clinician decide to transition from tesamorelin to MK-677:

1. Start MK-677 at 12.5 mg at bedtime while maintaining tesamorelin at 2 mg for 2 weeks.
2. Discontinue tesamorelin at the start of week 3.
3. Continue MK-677 12.5 mg for an additional 2 weeks.
4. Escalate to 25 mg MK-677 at week 5 if hunger and edema are tolerable.
5. Draw IGF-1 at week 12 from MK-677 initiation.

The 2-week overlap prevents a gap in IGF-1 support during the tesamorelin washout period, which has a half-life of approximately 26 to 38 minutes (the active metabolite, des-His¹-GHRH (1-44) amide, has a longer biological effect window of 4 to 6 hours per dose, but 24-hour IGF-1 support drops noticeably if injections stop abruptly).

Monitoring Schedule Comparison

| Parameter | Tesamorelin | MK-677 | |-----------|-------------|--------| | IGF-1 | Baseline, week 8, then every 6 months | Baseline, week 12 to 14, then every 6 months | | Fasting glucose / HbA1c | Baseline, month 3, then annually | Baseline, month 3, every 3 months if pre-diabetic | | Lipid panel | Baseline, month 6 | Baseline, month 6 | | Cortisol (fasting AM) | Not routinely required | Baseline, month 3 | | DEXA scan | Baseline, year 1 | Baseline, year 1 | | Blood pressure | Every visit | Every visit |

Contraindications and Who Should Avoid Each Drug

Tesamorelin is contraindicated in:

• Active malignancy or history of malignancy (the GHRH receptor may be expressed in some tumors)
• Pregnancy (Category X analog based on animal data per FDA labeling)
• Hypersensitivity to tesamorelin or mannitol
• Disruption of the hypothalamic-pituitary axis (e.g., hypophysectomy, pituitary tumor, head trauma)

MK-677 should be avoided in patients with:

• Type 2 diabetes or HbA1c above 6.5% at baseline (insulin resistance worsens)
• Active or prior history of hormone-sensitive malignancy
• Moderate-to-severe peripheral edema at baseline
• Known history of increased intracranial pressure

Neither drug has been studied in pregnancy, and both should be discontinued if a patient plans to conceive. The Endocrine Society Clinical Practice Guideline on GH axis disorders states explicitly: "GH or GH-stimulating therapy should be discontinued prior to conception and should not be used during pregnancy."